Introduction {#s1}
============

There is firm evidence that the early identification and treatment of subjects with psychotic disorder (PD) significantly improve their clinical outcome.^[@CIT0001]^ As clinical characteristics alone are of limited predictive value, there is a now a pressing need for further enhancement of predictive models to allow the earliest identification of subjects who may later develop psychosis.^[@CIT0002],[@CIT0003]^

Blood-based precursors of the PD may offer the opportunity to enhance predictive models and may provide important clues for our understanding of pathophysiological cascades which may later be expressed as psychosis or PD. Our recent review of blood biomarkers in the PD schizophrenia points to a convergence of pathophysiological mechanisms that involve the acute-phase response, glucocorticoid receptor signalling, coagulation, and lipid and glucose metabolism.^[@CIT0004]^ Furthermore, inflammatory cytokines, chemokines, and growth factors have been assessed in the blood during the perinatal periods and during childhood in subjects who subsequently developed schizophrenia, and in those with a first-episode psychosis.^[@CIT0005]^ These studies have, in general, demonstrated a picture of enhanced inflammatory tone during and preceding psychosis. While the basis of these changes is not clear, numerous risk factors for schizophrenia such as genetic background but also exposures to abuse, maternal stress during pregnancy, prenatal famine, obstetric complications, and adolescent cannabis use have all been described and hypothesized to lead to raised inflammatory tone.^[@CIT0010]^ Post-mortem brain studies, albeit possibly confounded by many variables, have furthermore underpinned the evidence for a role of inflammation, suggesting that this process is involved during early but also later stages of the disorder.^[@CIT0011]^

One of the main challenges of the field is to identify differential profiles which can be measured prior to the clinical onset of the PD. Previous studies of the ALSPAC cohort, a prospective general population cohort based in Bristol area in South West England have characterized subgroups of subjects who developed PD and Psychotic Experiences (PEs)^[@CIT0014]^ at age 18. These groups showed alterations in cortical white matter microstructure,^[@CIT0015]^ working memory,^[@CIT0016]^ and raised inflammatory markers in childhood^[@CIT0005]^ in subjects later developing PD and PE. Supported by this evidence, we employed a discovery proteomic study on blood plasma samples at age 11 in order to yield insights into the underlying protein pathways dysregulated in children with PD outcomes at age 18. As expression of PEs can be considered as a liability phenotype for PDs and may involve the same etiopathogenesis,^[@CIT0017]^ we next quantified candidate proteins in blood samples of subjects at age 11 in a separate subsample from the ALSPAC cohort, and compared subjects who reported PEs at age 18 with matched control subjects without PEs at age 18 as an verification study.

Methods {#s2}
=======

For extended materials and methods, please refer to online [supplementary methods](#sup4){ref-type="supplementary-material"}.

Participants {#s3}
------------

The ALSPAC cohort is a prospective general population cohort, and a rich resource of demographic, environmental, and clinical data on the individuals involved.^[@CIT0018]^ Written informed consent was obtained prior to taking the plasma samples. Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Please note that the study website contains details of all the data that is available through a fully searchable data dictionary (<http://www.bristol.ac.uk/alspac/researchers/access>).

Measures of PE and PD {#s4}
---------------------

PEs were identified at 11 and 18 years through the face-to-face, semi-structured Psychosis-Like Symptom (PLIKS) interview^[@CIT0014]^ conducted by trained psychology graduates in assessment clinics, and were coded according to the definitions and rating rules for the Schedules for Clinical Assessment in Neuropsychiatry, Version 2.0 (Organisation 1994). Interviewers rated PEs as not present, suspected or definitely psychotic. Cases of PD were defined as individuals with definite PEs that were not attributable to the effects of sleep or fever and when the PE occurred at least once per month over the past 6 months and caused severe distress, had a very negative effect on social/occupational function, or led to help seeking from a professional source.^[@CIT0014]^ All subjects categorized at the interview as having a PD met diagnostic criteria for PDs as defined in both DSM-IV and ICD-10, given that they had regular psychotic phenomena that were causing them severe distress or substantially impaired functioning.^[@CIT0014]^ Control samples from age-matched individuals without suspected or definite PEs, or PD at age 18 were randomly selected to match cases ([table 1](#T1){ref-type="table"}). With regard to psychotropic drug use, 8 of the 37 subjects (21.6%) with PD and who provided plasma samples were on psychotropic medication at age 18. No subjects reported psychotropic drug use at age 11. Subjects categorized as having disorder in our study only included those whose PEs were not attributed to drug use.^[@CIT0014]^

###### 

Descriptive Information for ALSPAC Subjects Included in the PD and PE Studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
                             Psychotic Disorder (PD)\           Psychotic Experiences (PE)\                                                 
                             Discovery Analysis                 Verification Analysis                                                       
  -------------------------- ---------------------------------- ----------------------------- --------------------------------------------- ------------------
  Number                     37                                 38                            40                                            66

  Gender                     29F, 8M                            28F, 10M                      22F, 18M                                      27F, 39M

  BMI at age 11, Mean (SD)   18.24 (3.39)                       18.066 (2.69)                 18.12 (2.72)                                  17.75 (2.52)

  Ethnicity                  28 W, 3 NW, 6 NA                   37 W, 1 NA                    37 W, 1 NW, 2 NA                              63 W, 0 NW, 3 NA

  PLIKS at age 12            20 none, 8 suspected, 9 definite   38 none                       40 none                                       60 none, 6 NA

  PLIKS at age 18            37 definite clinical               None                          29 = definite nonclinical, 11 = sleep/fever   66 none
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note:* For gender: F, female; M, male. Body mass index (BMI) at age 12 is reported, where missing BMI variables were replaced with the mean according to gender. For ethnicity: W, white; NW, non-white; NA, missing. PLIKS at age 12 and age 18 are reported, however, in this analyses, we used PLIKS at age 18 as the main outcome measure for our proteomic analysis.

Study Design {#s5}
------------

We undertook a nested case-control study of the ALSPC cohort and chose to assess all available plasma samples from age 11 children with outcomes of PD or PE at age 18. Available plasma samples from controls of age-matched individuals were then randomly selected to arrive at the sample size for each analysis. The present study consisted of analyses of two datasets harboring mass-spectrometry-based proteomic profiles. (1) Discovery proteomic analysis was performed on *n* = 37 individuals with an outcome of PD at age 18 vs *n* = 38 age-matched controls without PD or PE ([table 1](#T1){ref-type="table"}). (2) Hypothesis-driven proteomic analysis to confirm the discovery protein findings was performed on *n* = 40 individuals with an outcome of PE at age 18 vs *n* = 67 controls without PD or PE ([table 1](#T1){ref-type="table"}).

Blood Collection {#s6}
----------------

For all participants, blood samples from nonfasting individuals were collected at approximately 11 years of age. Blood was collected in 7.5 ml Plasma Lithium-Heparin S-Monovette tubes (Sarsted). Once collected, samples were stored on ice for a maximum of 90 min until processed. After centrifugation, the plasma was stored in aliquots at −80C. All samples underwent a single freeze-thaw cycle to allow aliquotting prior to the study. The standard quality of the plasma samples was ensured by assessing the overall MS protein profile to facilitate the identification of outlier protein expression profiles (see [supplementary figure S1](#sup6){ref-type="supplementary-material"}).

High-Abundance Protein Depletion of Plasma Samples {#s7}
--------------------------------------------------

To improve the dynamic range for proteomic analysis, 40 µl of plasma from each case was immunodepleted of the 14 most abundant proteins (alpha-1-antitrypsin, A1-acid glycoprotein, serum albumin, alpha2-macroglobulin, apolipoprotein A-I, apolipoptrotein A-II, complement C3, fibrinogen alpha/beta/gamma, haptoglobin, IgG A, IgG G, IgG M, transthyretin, and serotransferrin) using the Agilent Hu14 Affinity Removal System (MARS) coupled to a high-performance liquid chromatography (HPLC) system^[@CIT0019]^ ([supplementary methods](#sup4){ref-type="supplementary-material"}).

Sample Preparation for Mass Spectrometry {#s8}
----------------------------------------

Protein digestion and peptide purification was performed as previously described,^[@CIT0020]^ and are further detailed in [supplementary methods](#sup4){ref-type="supplementary-material"}.

Discovery Proteomic Analysis in PD {#s9}
----------------------------------

For the discovery proteomic analysis in PD (37 cases vs 38 controls; see [table 1](#T1){ref-type="table"}), 5 μl from each sample was injected on a Thermo Scientific Q-Exactive mass spectrometer, connected to a Dionex Ultimate 3000 (RSLCnano) chromatography system, and operated in data dependent analysis (DDA) mode, for label-free LC-MS/MS, which is standard proteomic profiling method for case/control clinical investigations.^[@CIT0020]^ Please refer [supplementary methods](#sup4){ref-type="supplementary-material"} for further details.

Hypothesis-driven Proteomic Analysis in PE {#s10}
------------------------------------------

For hypothesis-driven proteomic analysis of candidate proteins in a second subset of participants, we used targeted-data independent acquisition (DIA) analysis. Targeted-DIA is currently the gold standard for high-throughput quantification of protein targets.^[@CIT0023]^ For targeted-DIA in the PE subset of participants (40 cases vs 66 controls; [table 1](#T1){ref-type="table"}), 5 μl of each sample was injected on the Thermo Scientific Q-Exactive, and data was acquired in DIA mode. The DIA isolation scheme and multiplexing strategy were based on that from Egertson et al., in which five separate 4-*m*/*z* isolation windows are analyzed per spectrum^[@CIT0026],[@CIT0027]^ ([supplementary methods](#sup4){ref-type="supplementary-material"}).

Bioinformatics and Statistical Analysis {#s11}
---------------------------------------

### Discovery Proteomic Analysis in PD. {#s12}

Label-free quantification for our discovery DDA files generated from the PD subjects was performed in Max Quant (v1.5.2.8),^[@CIT0028],[@CIT0029]^ as described.^[@CIT0020]^ Only proteins present in \>80% of samples in at least one group were taken forward for quantification (supplementary table 1; *n* = 181 proteins), whereby the data were log2 transformed and normalized ([supplementary figure S1](#sup6){ref-type="supplementary-material"}).^[@CIT0030]^ Data management and analyses were then performed in R version 3.0.1 (2013-05-16). Missing proteomic data was replaced with a random value from the normal distribution of each protein that was created separately for cases and controls.^[@CIT0031]^ Linear regression analyses were performed on all proteins with the subject sample as a random effect, adjusting for gender and BMI at age 11. We adjusted for BMI as the prevalence of obesity in people with mental illness has been reported to higher than the general population,^[@CIT0032],[@CIT0033]^ and recent evidence suggests childhood BMI between the ages 7 and 13 years is associated with risk of schizophrenia.^[@CIT0034]^ A 5% false discovery rate (FDR) threshold was applied using the "fdrtool" package in R, as previously described.^[@CIT0035],[@CIT0036]^ The demographic and clinical data were tested for differences between case and control group using the Fisher's Exact test.

### Hypothesis-Driven Proteomic Analysis in PE. {#s13}

All DIA files from the PE analysis (see [table 1](#T1){ref-type="table"} for groups) were analyzed in Skyline (V3.5.0; <https://skyline.gs.washington.edu>), as detailed by Egertson et al.^[@CIT0026],[@CIT0027]^ We aimed to verify; (1) the specific proteins identified as differentially expressed following FDR from our "***Discovery proteomic analysis in PD"*** and (2) the broader set and proteins from the complement and coagulation pathways which were generally implicated from the *Discovery proteomic analysis in PD'*. This was done in a separate ALSPAC subgroup of participants with a milder phenotype of PE (*n* = 40) but not PD at age 18, compared to controls (*n* = 66; [table 1](#T1){ref-type="table"}). For a full list of the fragments targeted and quantified please refer to [supplementary table S2](#sup2){ref-type="supplementary-material"}. All peptides and associated fragment ions were visually checked, and peak editing was undertaken where necessary ([supplementary document 1](#sup5){ref-type="supplementary-material"}). Preprocessing and statistical analysis of the fragment level data were undertaken in mapDIA^[@CIT0037]^ ([supplementary table S3](#sup3){ref-type="supplementary-material"}), as detailed in [supplementary methods](#sup4){ref-type="supplementary-material"}.

Pathway Analysis {#s14}
----------------

KEGG pathway analysis is traditionally performed on all proteins that are differentially expressed (*P* \< .05) (<http://www.genome.jp/kegg/pathway.html>) in order to identify coordinated changes in pathways and cellular processes at the level of the proteome, and this was therefore undertaken on all proteins differentially expressed in the arising from the PD study. The STRING database (<http://string-db.org/>)^[@CIT0038]^ was used to analyze the protein--protein interactions and pathway relationships within our dataset.

Results {#s15}
=======

Discovery Proteomic Analysis in PD {#s16}
----------------------------------

For the discovery proteomic analysis in PD (37 cases vs 38 controls; [table 1](#T1){ref-type="table"}), we identified 345 proteins (FDR \< 0.01), of which 181 were present in \>80% of samples and were taken forward for analysis (supplementary table 1). Sixty proteins out of 181 were significantly differentially expressed between PD cases and controls (*P* \< .05), following adjustment for gender and BMI as covariates (see results, [table 2](#T2){ref-type="table"}). Thirty-four proteins (A2M, TNXB, IGHM, CLEC3B, BCHE, GSN, ECM1, IGF2, C4BPB, CTBS, SERPINA7, VCAM1, LUM, GPLD1, HABP2, IGHG3, SEPP1, CFH, SERPINF1, F5, F9, IGFBP3, F12, CFD, CFI, LAMP2, CRTAC1, PCOLCE, AFM, PLG, COL6A3, C7, APOA2, CD109) remained significant after FDR ([table 2](#T2){ref-type="table"}). The full list of proteins profiled, and those that were differentially expressed between groups is provided in supplementary table 1.

###### 

Differential Protein Expression in Psychotic Disorder

  Gene Names   Protein Names                                             Protein ID   *P* Value           FC in PD   FDR
  ------------ --------------------------------------------------------- ------------ ------------------- ---------- -------------------
  A2M          Alpha-2-macroglobulin                                     P01023       2.35E-05            −1.36      0.002452739084173
  TNXB         Tenascin-X                                                P22105       6.78E-05            1.60       0.003010022721392
  IGHM         Ig mu chain C region                                      P01871       8.93E-05            −1.49      0.003100233074614
  CLEC3B       Tetranectin                                               P05452       0.000238536918096   1.21       0.005527149972427
  BCHE         Cholinesterase                                            P06276       0.00028867379359    1.22       0.006016201946107
  GSN          Gelsolin                                                  P06396       0.001184331262904   1.13       0.013741065106703
  ECM1         Extracellular matrix protein 1                            Q16610       0.00156813706243    1.23       0.015289744574204
  IGF2         Insulin-like growth factor II                             P01344       0.00185038627232    1.26       0.016146280605035
  C4BPB        C4b-binding protein beta chain                            P20851       0.001968111624603   −1.31      0.016452583474952
  CTBS         Di-N-acetylchitobiase                                     Q01459       0.002116574187167   1.23       0.016804037125592
  SERPINA7     Thyroxine-binding globulin                                P05543       0.002123057983554   1.17       0.016818582457348
  VCAM1        Vascular cell adhesion protein 1                          P19320       0.002249659902707   1.34       0.01709034422445
  LUM          Lumican                                                   P51884       0.002278966387226   1.19       0.017150104571853
  GPLD1        Phosphatidylinositol-glycan- specific phospholipase D     P80108       0.00234614616507    1.42       0.017282940815611
  HABP2        Hyaluronan-binding protein 2                              Q14520       0.002538350481953   1.17       0.017633778389896
  IGHG3        Ig gamma-3 chain C region                                 P01860       0.002874794375478   −1.27      0.018546283526309
  SEPP1        Selenoprotein P                                           P49908       0.003146451379488   1.21       0.019193243065463
  CFH          Complement factor H                                       P08603       0.003414262231026   1.13       0.019765573474774
  SERPINF1     Pigment epithelium-derived factor                         P36955       0.003757243579115   1.13       0.02047865413338
  F5           Coagulation factor V                                      Q28107       0.004067608434137   1.27       0.021055629451341
  F9           Coagulation factor IX                                     P00740       0.004334224194447   1.13       0.021506865940923
  IGFBP3       Insulin-like growth factor- binding protein 3             P17936       0.007644758410206   1.17       0.032388279082007
  F12          Coagulation factor XII                                    P00748       0.007824122898499   1.19       0.032887687197417
  CFD          Complement factor D                                       P00746       0.008444673418423   1.35       0.034556546176356
  CFI          Complement factor I                                       P05156       0.010003939954609   1.12       0.038384336560269
  LAMP2        Lysosome-associated membrane glycoprotein 2               P13473       0.011818700619699   1.19       0.042278849036246
  CRTAC1       Cartilage acidic protein 1                                Q9NQ79       0.012282687547432   1.23       0.043191407027815
  PCOLCE       Procollagen C-endopeptidase enhancer 1                    Q15113       0.012858286614664   1.19       0.044281235146809
  AFM          Afamin                                                    P43652       0.014449995361757   1.12       0.047073156606685
  PLG          Plasminogen                                               P00747       0.014808887658904   1.14       0.047661474616677
  COL6A3       Collagen alpha-3(VI) chain                                P12111       0.015123384190082   1.35       0.048165491709375
  C7           Complement component C7                                   P10643       0.015253718180595   1.14       0.048371295829491
  APOA2        Apolipoprotein A-II                                       P02652       0.015768184543684   −1.35      0.049166640144774
  CD109        CD109 antigen                                             Q6YHK3       0.016302896370883   1.23       0.049965576376137
  ACTG1        Actin, cytoplasmic 2                                      P63261       0.01842844064171    1.23       0.052893098007721
  CD14         Monocyte differentiation antigen CD14                     P08571       0.018648336393252   1.14       0.05317487598941
  KLKB1        Plasma kallikrein                                         P03952       0.019913520723869   1.11       0.054727223568396
  KNG1         Kininogen-1                                               P01042       0.021034485331523   1.11       0.056011643691759
  F5           Coagulation factor V                                      P12259       0.021375886441285   1.14       0.056387118262621
  SERPINF2     Alpha-2-antiplasmin                                       P08697       0.024325248700793   1.09       0.059359684835652
  C1S          Complement C1s subcomponent                               P09871       0.024366317843667   1.12       0.059397936011767
  F2           Prothrombin                                               P00734       0.024740545362472   1.12       0.059742847153768
  APOA4        Apolipoprotein A-IV                                       P06727       0.025696265563249   1.13       0.060594940495585
  IGKV2D-40    Ig kappa chain V-II region TEW                            A0A075B6R1   0.025902708420233   −1.20      0.060773774727794
  LYVE1        Lymphatic vessel endothelial hyaluronic acid receptor 1   Q9Y5Y7       0.026443478521856   1.24       0.061233787247234
  F13A1        Coagulation factor XIII A chain                           P00488       0.027407334083503   1.14       0.062086047473999
  S100A8       Protein S100-A8                                           P05109       0.030888403899574   1.24       0.065695245585865
  ANPEP        Aminopeptidase N                                          P15144       0.030918599644144   1.22       0.065724623760281
  VTN          Vitronectin                                               P04004       0.031818887929209   1.10       0.066586456714209
  C4BPA        C4b-binding protein alpha chain                           P04003       0.034467677540817   −1.17      0.068973446582385
  APOH         Beta-2-glycoprotein 1                                     P02749       0.035328247276582   1.13       0.06970463250612
  C6           Complement component C6                                   P13671       0.036921822018089   1.10       0.071005866471262
  C1R          Complement C1r subcomponent                               P00736       0.03697367472293    1.13       0.07104710171526
  CLU          Clusterin                                                 P10909       0.037047254149251   1.09       0.071105498589918
  COMP         Cartilage oligomeric matrix protein                       P49747       0.038053606817258   1.27       0.071890746567978
  CPN2         Carboxypeptidase N subunit 2                              P22792       0.039032541881775   1.11       0.07263130677403
  ADIPOQ       Adiponectin                                               Q15848       0.041918375605006   1.28       0.076309890815356
  ATRN         Attractin                                                 O75882       0.045675287259397   1.09       0.080866376756604
  VASN         Vasorin                                                   Q6EMK4       0.047805918283872   1.15       0.083340993340051
  RARRES2      Retinoic acid receptor responder protein 2                Q99969       0.048852426112363   1.15       0.084528878416831

*Note:* Label-free discovery proteomic was used to compare age 11 plasma samples from children with an outcome of PD at age 18 with age-matched healthy controls (*n* = 75). Sixty proteins were identified as significantly differentially expressed between cases and controls (ANCOVA, *P* \< .05), following adjustment for gender and BMI as covariates (supplementary table 1). The gene name, protein name, accession, ANCOVA adjusted *P* value, fold change (FC) in disorder, and false discovery rate (FDR) values are listed for the 60 significant proteins which are sorted by FDR.

Pathway Analysis {#s17}
----------------

To identify potential protein pathways and processes whose expression is co-ordinately altered in PD, we uploaded the 60 significant proteins to KEGG for pathway analysis. The top pathway implicated was the "Complement and Coagulation Cascade" ([figure 1a](#F1){ref-type="fig"}; Fisher's exact test *P* = 8.56 × 10^−32^), followed by *Staphylococcus aureus* infection and *Pertussis* infection protein pathways ([figure 1a](#F1){ref-type="fig"}). In addition, when the same proteins were analyzed using the STRING algorithm, the set of coagulation and complement proteins were found to cluster together as subnetworks ([figure 1b](#F1){ref-type="fig"}), providing further evidence of coordinated perturbation of these pathways.

![Differentially expressed proteins converge on complement and the coagulation cascade. (a) KEGG pathway analysis 60 proteins as differentially expressed between cases (*n* = 37) and controls (*n* = 38) identified the complement and coagulation cascade as the top process implicated (19 proteins; false discovery rate (FDR) 8.56e-32; (b) STRING network analysis provided strong evidence for co-regulation among coagulation and complement proteins, with the average interactions per protein being 3.65 (ie, *average node degree*) for 57 of the 60 proteins mapped. Proteins that were significant at the FDR level are marked with asterisks.](sbx07501){#F1}

Hypothesis-Driven Proteomic Analysis in PE {#s18}
------------------------------------------

These analyses aimed to verify and extend the findings of the discovery analysis of PD in a separate ALSPAC subgroup of participants with a milder phenotype of PE (*n* = 40) but not PD at age 18, compared to controls (*n* = 66; [table 1](#T1){ref-type="table"}). Two PE cases were excluded from the bioinformatics analysis due to poor chromatographic profiles.

We used a targeted-DIA approach (see [supplementary document 1](#sup5){ref-type="supplementary-material"}) to quantify the levels of the 34 FDR significant proteins in the PE group. Twenty-seven of the 34 FDR candidates had peptides suitable for targeted-DIA analysis ([supplementary table S3](#sup3){ref-type="supplementary-material"}). We also used a targeted-DIA approach to target the proteins which mapped to the complement and coagulation cascade in PD but which were not in the list of the 34 FDR significant proteins ([table 2](#T2){ref-type="table"}). Thus of the total of 19 proteins which mapped to the complement and coagulation cascade ([figure 1](#F1){ref-type="fig"}), we had already assessed 10 when undertaking our targeted-DIA assessment of the 34 FDR significant proteins, leaving 9 proteins (significant at *P* \< .05) which mapped to this process ([figure 1](#F1){ref-type="fig"}), and we assessed these 9. Therefore a total of 36 protein candidates (27 + 9) were quantified in the hypothesis-driven PE study. Out of the 36 targets, we confirmed the differential expression of 10 proteins using a Bayesian latent variable model at a 5% FDR threshold (C4BPA, A2M, PLG, AFM, CFH, IGHG3, VTN, GSN, C4BPB, and IGHM; [supplementary table S3](#sup3){ref-type="supplementary-material"}). The protein level DIA data illustrates that the direction of protein expression changes in the PD and PE phenotypes compared to controls was the same for all of these 10 proteins ([figure 2](#F2){ref-type="fig"}).

![Bean plots of proteins identified as altered in the same direction in both the psychotic disorder (PD) and psychotic experience (PE) cohorts. Bean plots represent the log-transformed intensities in protein expression (*y*-axis) between cases and controls (*x*-axis) for both the PD (*n* = 75) discovery proteomic analysis (left), and PE (*n* = 106) hypothesis-driven proteomic analysis (right). Please note the scale on the *y*-axis differs between the PD and PE cohorts because different quantification methods were used to assess protein expression in each cohort (ie, DDA vs DIA data). Nevertheless, bean-plots representing the expression changes in complement and coagulation proteins (A2M, PLG, C4BPA, C4BPB, CFH, and VTN), and others (IGHM, IGHG3, GSN, and AFM) are altered in the same direction in both cohorts. These protein candidates may represent persistent early hallmarks of psychotic outcomes at age 18 in the general population.](sbx07502){#F2}

Discussion {#s19}
==========

An urgent challenge in the field of psychosis is to understand the pathophysiological basis of psychosis so that early prediction can be realized and earlier and more effective prevention and treatment options can be considered. We have undertaken the first discovery proteomic profiling study in early adolescence in order to identify differential plasma protein expression preceding PD. Using a unique prospective cohort, we investigated blood plasma samples obtained from children at age 11 who went on to develop PD at age 18. In the samples collected at age 11, we identified a set of 34 proteins significantly differentially expressed between children who developed PD vs age-matched population-based controls ([table 2](#T2){ref-type="table"}). Seven of these 34 proteins (A2M, APOA2, C4BPB, CLECB3, GPLD1, IGHM, IGFBP3) have previously been implicated in blood-based biomarker studies of patients diagnosed with the PD schizophrenia.^[@CIT0004]^ These proteins, therefore, might have potential value in predicting the risk of and in contributing to future pathophysiological models for PD. However, this will require robust identification of markers, calibration of risk prediction models, and testing in independent cohorts.

The information that can be derived from the broader pathway- or network-based picture of differential protein expression (rather than the individual proteins) is relevant to understanding the biological basis of the PD. Pathway analysis identified the Complement and Coagulation Cascade as the most significant process altered ([figure 1](#F1){ref-type="fig"}), with a total of 19 proteins involved in the process being differentially expressed between groups. These complement and coagulation proteins included 3 decreased proteins (A2M, C4BPA, C4BPB) and 16 increased proteins (C1R, C1S, C6, C7, CFD, CFH, CFI, F12, F13A1, F2, F5, F9, KLKB1, KNG1, PLG, SERPINF2) in children who developed PD. Due to significant overlap in proteins that mapped to the other top infection related processes in *Staphylococcus* and *Pertussis* infection, we focused our attention on complement and coagulation cascade. We followed the above discovery study with a hypothesis-driven proteomic study of children who went on to develop PEs (rather than PD) at age 18. In this group, we confirmed the differential expression of 10 proteins which were altered in the PD group, and all of these changes were in the same direction as in the PD group ([figure 2](#F2){ref-type="fig"}). Six of these targeted proteins were implicated in complement and coagulation (A2M, C4BPA, C4BPB, CFH, PLG, VTN), two in the immune system (IGHM and IGHG3), and one each in Vitamin E binding (AFM), and synaptic elimination and myelination (GSN). As PEs is a milder phenotype that PD, with about 8% of individuals ultimately transitioning to PD,^[@CIT0013]^ we consider these results to be supportive of our main findings.

The complement and coagulation cascade is part of the innate immune defense against infection, and the role of these processes in the pathophysiology of schizophrenia has gained attention in recent years. After decades of intensive research, collaborative GWAS efforts identified the strongest risk association for schizophrenia in the major histocompatibility complex (MHC)---best known for its role in immunity.^[@CIT0039]^ Sekar et al^[@CIT0013]^ have recently shown that within this MHC region the strongest risks are associated with the complement 4 (C4) gene, which reflects the heritable impairment in the complement system in schizophrenia. In this study, we found 9 complement proteins dysregulated in children preceding the onset of PD, including decreased C4BPA and C4BPB, and increased C1R, CFD, C1S, CFI, C6, C7, and CFH. The C4BPA and C4BPB proteins assemble together forming C4b-binding protein,which regulates the activation of the complement cascade, and also has a regulator role in the coagulation system. The coagulation system was also largely increased in expression in children preceding the onset of PD, including increased KNG1, PLG, KLKB1, F12, F9, F5, F13A1, SERPINF2, F2, and decreased A2M. In support, Li et al^[@CIT0040]^ also reported the complement and coagulation cascade as the most significant pathway implicated in plasma samples of drug naïve schizophrenia patients, and again reported on the reduced expression of C4BPB. Other blood-based proteomic studies of first-episode psychosis support these findings.^[@CIT0019],[@CIT0041],[@CIT0042]^ Dysfunction in coagulation has also been reported previously in schizophrenia^[@CIT0004],[@CIT0043],[@CIT0044]^ and more recently by Hoirisch-Clapauch et al,^[@CIT0045]^ who observed that schizophrenia patients on chronic warfarin therapy showed remission of psychotic symptoms. The complement system is linked functionally with inflammation,^[@CIT0046]^ and within the brain has important functions in the regulation of synaptic plasticity.^[@CIT0013],[@CIT0047]^ Our findings are thus in keeping with the literature implicating inflammation in major psychiatric disorders^[@CIT0010],[@CIT0050]^ and with potential mechanisms involved in complement and altered synaptic plasticity.^[@CIT0013],[@CIT0051]^ However, the functional relationship between complement activation within the blood and the complement activation within the brain has not been elucidated, and hence we cannot draw a direct inference between our findings and brain function. In the light of our findings, future studies need to address this issue.

Our study has several limitations which should be mentioned. Firstly, it was based on a unique characterized cohort, and we could not access an exactly similar age-matched sample in which we could perform a direct replication of the discovery analyses. However, we obtained supportive complementary data for our hypothesis-driven study using age 11 samples from a subject with PE outcomes, rather than PD outcomes, from the same cohort. Nevertheless, it has been argued that PEs form a measurable liability phenotype for PD and that PEs share (at least some of) the risk factors of PD, suggesting that their etiopathogenesis may involve similar biological cascades. Another potential weakness is that the subjects investigated in this study were age 18 at the time of last clinical assessment and therefore have not yet gone through the full period of risk for developing a PD and hence our sample is not representative of all individuals with the PD. While future work will be required to address this, it is notable that our findings find significant support from the plasma proteomic biomarker literature of schizophrenia which has implicated the complement and coagulation pathways very consistently.^[@CIT0004],[@CIT0017],[@CIT0029],[@CIT0030],[@CIT0031]^ Finally, while various approaches for bioinformatics analyses of DIA datasets are still under development, the methods we used are in line with recent advances in the bioinformatic handling of DIA data by Teo et al.^[@CIT0037]^ This tool considers the fragment level data as "repeated measurements" of the abundance of peptides and thus applies a sophisticated hierarchical Bayesian algorithm^[@CIT0037]^ for the analysis of DIA data (supplementary table 3).

In conclusion, our study which is the first to undertake a proteomic analysis of plasma in childhood from subjects who develop PD in early adulthood has identified alterations in the complement and coagulation process. These changes are also present, but to a lesser extent, among subjects who go on to develop PE in early adulthood, suggesting that our findings may represent early changes associated with a vulnerability to psychosis. Further clarification of the roles of these proteins and processes will be obtained from future studies which will test how baseline levels of these proteins in subjects at ultra-high risk for PD relate to the varied clinical outcomes.^[@CIT0054]^ Overall, our findings are indicative of the presence of a pathophysiological process long before the development of the disorder, and suggest that blood-based profiles may be tested in larger population for their value in predicting later PD.
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